Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Thomas Jefferson University
Thomas Jefferson University
Dana-Farber Cancer Institute
University Health Network, Toronto
ImmuneSensor Therapeutics Inc.
Bolt Biotherapeutics, Inc.
University of Kentucky
Bristol-Myers Squibb
Navire Pharma Inc., a BridgeBio company
Molecular Templates, Inc.
Wake Forest University Health Sciences
Mirati Therapeutics Inc.
Fate Therapeutics
Assistance Publique Hopitaux De Marseille
Alliance Foundation Trials, LLC.
H. Lee Moffitt Cancer Center and Research Institute
Calithera Biosciences, Inc
Alliance Foundation Trials, LLC.
WindMIL Therapeutics
Duke University
National Cancer Centre, Singapore
Novartis
Incyte Corporation
RTOG Foundation, Inc.
Fox Chase Cancer Center
Eli Lilly and Company
Brown University
Incyte Corporation
University of Washington
Western Regional Medical Center